Login to Your Account



Are More Financial Disclosure Requirements in the Works?

By Mari Serebrov


Thursday, May 26, 2011
WASHINGTON – Citing as their prime evidence Sanofi's strategy to prevent approval of Lovenox biosimilars, two senators are building a case for more disclosure of biopharma's financial ties with nonprofit medical groups, especially when those nonprofits intervene on drug approvals and safety issues.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription